ClinicalTrials.gg
CompletedNCT03252821Updated Mar 17, 2020

Effects of High-intensity Training Compared to Resistance Training in Cancer Patients Undergoing Radiotherapy

An interventional study of High-intensity interval training and Resistance training in Prostate Cancer, Head and Neck Cancer and Rectum Cancer, sponsored by Cliniques universitaires Saint-Luc- Université Catholique de Louvain. Completed at 1 site in Belgium. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-03-17.

Sponsored by Cliniques universitaires Saint-Luc- Université Catholique de Louvain · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
78
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The aim of this study is to assess the impact of a high-intensity aerobic training and resistance training on fatigue in prostate, head and neck and rectum cancer patients undergoing radiotherapy.

A three-arm randomized controlled trial will be conducted. Patients will be randomised into either a high-intensity aerobic training group or a resistance training group or a control group. Participants in the training groups will exercised for five to eight weeks. Exercise sessions will be take place 3 days per week under the supervision of an experienced therapist. Subjects will be assessed at baseline and post-intervention. The primary outcome will be fatigue measured using the FACIT-fatigue questionnaire. The secondary outcomes will be: functional capacity, quality of life, executive functions, sleep disturbances, somnolence syndrome, insomnia, depression symptoms.

02

Conditions studied

  • Prostate Cancer
  • Head and Neck Cancer
  • Rectum Cancer
03

In context

Prostatic Neoplasms

6,484 studies on the registry are indexed under Prostatic Neoplasms; 1,415 are open to participants now.

This study's enrollment of 78 is above the median of 58 across 4,908 interventional studies indexed under Prostatic Neoplasms.

Browse Prostatic Neoplasms studies →

Lead sponsor

Cliniques universitaires Saint-Luc- Université Catholique de Louvain is the lead sponsor of 348 studies on the registry; 62 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • a primary diagnosis of prostate cancer, head and neck cancer (oral cavity, pharynx, larynx, nasal cavity/sinuses, or salivary gland) or rectum cancer;
  • age over 18 years;
  • no distant metastases and/or disease progression;
  • at least 25 scheduled radiation treatments (5 weeks);
  • ability to read, write, and speak French.

Exclusion criteria

Exclusion criteria :

  • uncontrolled cardiac, hypertensive or pulmonary diseases,
  • uncontrolled insulin-dependent diabetes mellitus,
  • neuropsychiatric disorders or orthopaedic conditions that would impair exercise participation
  • abnormal electrocardiogram.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
78 participants (actual)

Study arms

  • Experimental
    High-intensity aerobic training group

    High intensity interval training

    Behavioral: High-intensity interval training

  • Active comparator
    Resistance training group

    Muscle strengthening

    Behavioral: Resistance training

  • No intervention
    Control group

    Usual care

Interventions

  • BehavioralHigh-intensity interval training

    High-intensity interval training sessions will be conducted on cycle ergometers or treadmill with heart rate measured throughout each session.

  • BehavioralResistance training

    Resistance exercise will be performed on eight exercises targeting major muscle groups at 60% to 85% of their estimated one-repetition maximum (1RM).

06

What researchers measure

Primary outcomes

  1. Change in fatigue

    Fatigue is measured by FACIT-fatigue questionnaire

    Time frame: Assessments at baseline and 5 weeks (rectum cancer) or 7 weeks (head and neck cancer) or 8 weeks (prostate cancer)

Secondary outcomes

  1. Change in functional capacity

    Functional capacity is measured by 6-minute walk test

    Time frame: Assessments at baseline and 5 weeks (rectum cancer) or 7 weeks (head and neck cancer) or 8 weeks (prostate cancer)

  2. Change in quality of life

    Quality of life is measured by Functional Assessment of Cancer Therapy-General

    Time frame: Assessments at baseline and 5 weeks (rectum cancer) or 7 weeks (head and neck cancer) or 8 weeks (prostate cancer)

  3. Change in sleep disturbances

    Sleep disturbances are measured by Pittsburgh Sleep Quality Index

    Time frame: Assessments at baseline and 5 weeks (rectum cancer) or 7 weeks (head and neck cancer) or 8 weeks (prostate cancer)

  4. Change in somnolence syndrome

    Somnolence syndrome is measured by Epworth Sleepiness Scale

    Time frame: Assessments at baseline and 5 weeks (rectum cancer) or 7 weeks (head and neck cancer) or 8 weeks (prostate cancer)

  5. Change in insomnia

    Insomnia is measured by Insomnia Severity Index

    Time frame: Assessments at baseline and 5 weeks (rectum cancer) or 7 weeks (head and neck cancer) or 8 weeks (prostate cancer)

  6. Change in depression symptoms

    Depression symptoms are measured by Center for Epidemiologic Studies Depression Scale

    Time frame: Assessments at baseline and 5 weeks (rectum cancer) or 7 weeks (head and neck cancer) or 8 weeks (prostate cancer)

  7. Change in executive functions

    Executive functions is measured by the Trail Making Test

    Time frame: Assessments at baseline and 5 weeks (rectum cancer) or 7 weeks (head and neck cancer) or 8 weeks (prostate cancer)

  8. Change in dyspnea

    Dyspnea is measured by Multidimensional Dyspnea Profile

    Time frame: Assessments at baseline and 5 weeks (rectum cancer) or 7 weeks (head and neck cancer) or 8 weeks (prostate cancer)

  9. Adherence

    Percentage of completed sessions

    Time frame: Weekly through the intervention (during 8 weeks)

07

Study locations

1 site
  • Cliniques universitaires Saint-Luc
    Brussels, 1200, Belgium
08

References and documents

Publications

  • Piraux E, Reychler G, Vancraeynest D, Geets X, Leonard D, Caty G. High-intensity aerobic interval training and resistance training are feasible in rectal cancer patients undergoing chemoradiotherapy: a feasibility randomized controlled study. Rep Pract Oncol Radiother. 2022 May 19;27(2):198-208. doi: 10.5603/RPOR.a2022.0036. eCollection 2022. PubMed 36299392 ↗

Individual participant data

Plan to share: Undecided

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 17, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03252821
Responsible party
Caty Gilles (Principal Investigator, Cliniques universitaires Saint-Luc- Université Catholique de Louvain) — Principal investigator
First posted
Aug 17, 2017
Start date
Aug 15, 2017
Primary completion
Sep 1, 2019
Completion
Sep 20, 2019
Last update
Mar 17, 2020

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion